Phase IIa, Open Label, Dose Ascending Study to Determine the Maximum Tolerated Dose, Safety and Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Lanreotide PRF in Subjects With Acromegaly Previously Treated and Controlled With Either Octreotide LAR or Lanreotide Autogel
Phase of Trial: Phase II
Latest Information Update: 04 Jul 2017
At a glance
- Drugs Lanreotide (Primary)
- Indications Acromegaly
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Ipsen
- 04 Jul 2017 The trial has been completed in Germany as per European Clinical Trials Database record; EudraCT2014-002389-62.
- 10 Jun 2017 Biomarkers information updated
- 11 Feb 2017 As per European Clinical Trials Database study is suspended in Czech Republic.